AbCellera Presents New Data On Two T-Cell Engager Programs At SITC 2023
Portfolio Pulse from Benzinga Newsdesk
AbCellera has presented new data from its T-cell engager platform at SITC 2023. The data shows that diverse CD3-binding antibodies can optimize T-cell engager function beyond what is possible by modifying a single CD3-binder.
November 03, 2023 | 4:07 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
AbCellera's new data presentation at SITC 2023 shows potential for optimization of T-cell engager function. This could potentially lead to advancements in their product offerings.
The new data presented by AbCellera at SITC 2023 shows potential for optimization of T-cell engager function. This could lead to advancements in their product offerings, which could potentially increase the company's market share and profitability. Therefore, this news is likely to have a positive impact on AbCellera's stock price in the short term.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100